Pep Guardiola issues Huddersfield warning

first_imgManchester City will play on Sunday against this “tough” rival says coach Guardiola, in what will be the Citizens first home game of the seasonManchester City opened the 2018-2019 Premier League season with a win over Arsenal last week.And now, they will host Huddersfield at Etihad Stadium on Sunday.But the Citizens’ boss Pep Guardiola doesn’t want any surprises and has warned their team about their “tough” opponent.“Last season was tough, those games,” City manager Guardiola said as reported by The National.Harry Maguire, Manchester UnitedSolskjaer praises Harry Maguire after Man United’s 1-0 win Andrew Smyth – September 14, 2019 Ole Gunnar Solskjaer singled out Harry Maguire for praise after helping Manchester United keep a clean sheet in their 1-0 win over Leicester City.“They defended so well.”“They are so tough – physicality, defensively strong, good set-pieces, good throw-ins, good counter-attack, good high pressing,” he explained.“It was complicated last season and I imagine quite similar games.”“In this part of the season, all the teams, especially those with a lot of players at the World Cup, you need time – one month or a month and a half”, he added.“In this period, these kind of games are so dangerous for the players. Games like this – and Wolves, Cardiff, Fulham – I prefer these teams in October/November.”last_img read more

Ponzio Palacios is a readymade Real Madrid player

first_imgRiver Plate captain Leonardo Ponzio believes team-mate Exequiel Palacios is a suitable player for Real Madrid to signThe 20-year-old midfielder has been strongly linked with a move to Real in the January transfer window with River president Rodolfo D’Onofrio confirming there has been contact.Palacios is regarded as one of the brightest young prospects in South America and had reportedly captured the interest of several European giants.Now Ponzio believes his young team-mate would fit in well at Real as he has all the required attributes.FC Barcelona, Valencia CFMatch Preview: Barcelona vs Valencia Boro Tanchev – September 14, 2019 Is derby time in La Liga, as Barcelona welcomes Valencia to the Camp Nou Stadium tonight at 21:00 (CET).“He has been with us for almost two and a half years,” Ponzio told AS. “He has become a player in River, in Argentine soccer.“Real Madrid? I believe what ability he has. Of course, you cannot ask him to be the same as Luka Modric. He is 20 years old. He goes to another continent, to another kind of football.“But conditions have to grow. He is very of the palate of Real Madrid. Technically he is good, he has a good footing, individually he is good. But he must keep his head. He has to be calm because he is going to make the jump at any moment.”Real have now travelled the United Arab Emirates for Wednesday’s Club World Cup semi-final against Kashima Antlers.last_img read more

Elon Musk offers glimpse of SpaceXs 60 internet satellites ahead of launch

first_img 13 Photos Sci-Tech Internet Services “First 60 @SpaceX Starlink satellites loaded into Falcon fairing. Tight fit,” he wrote.The company is hoping to launch on Tuesday or Wednesday, but Musk also warned that “much will likely go wrong” with this first mission and that the company will need to make six more launches of 60 satellites required for minor coverage and double that for moderate.Musk highlighted that these satellites are “production design,” unlike February 2018’s proof of concept Tintin launch. Gwynne Shotwell, SpaceX’s president and chief operating officer, said last week that these are still only scaled-down test models — the company will start launching satellites for actual service later in 2019, according to Space News. Now playing: Watch this: Share your voice 4:34 Comment SpaceX’s Starlink satellites will go to space on a Falcon 9 rocket. SpaceX Elon Musk gave us a look at his company’s Starlink internet satellites ahead their trip beyond our world in a Falcon 9 rocket.The SpaceX boss tweeted a shot of the satellites flat-packed in the rocket’s nose cone. Meet the SpaceX Falcon Heavy, the world’s most powerful rocket 1 Tags First 60 @SpaceX Starlink satellites loaded into Falcon fairing. Tight fit. pic.twitter.com/gZq8gHg9uK— Elon Musk (@elonmusk) May 12, 2019 SpaceX ultimately plans to launch a constellation of nearly 12,000 satellites, according to Federal Communications Commission filings from March and November 2018.Musk reportedly fired at least seven senior managers over disagreements about the program’s pace last June.First published at 4:21 a.m. PT.Updated at 5:05 a.m. PT: Adds more detail. Watch SpaceX Falcon Heavy rocket nail an historic landing Elon Musk Space SpaceXlast_img read more

PM to lead 22member team in Oikya Front dialogue

first_imgPrime Minister Sheikh Hasina. File PhotoAwami League president, prime minister  Sheikh Hasina will lead a 22-member delegation of the 14-party alliance to the dialogue with the leaders of the Jatiya Oikya Front on Thursday.The talks will be held at the prime minister’s official Ganabhaban residence at 7pm on Thursday.The delegation would include AL general secretary Obaidul Quader, advisory council members Amir Hossain Amu and Tofail Ahmed, presidium members Matia Chowdhury, Sheikh Fazlul Karim Selim, Mohammad Nasim, Md Abdur Razaque, Kazi Zafarullah and Ramesh Chandra Sen, joint general secretaries Mahbubul Alam Hanif, Dipu Moni, Abdur Rahman and Jahangir Kabir Nanok, office secretary Abdus Sobhan Golap, publicity and publication secretary Hasan Mahmud, law secretary SM Rezaul Karim, law minister Anisul Huq, Samyabadi Dal general secretary Dilip Barua, Bangladesh Workers Party president Rashed Khan Menon, president of a faction of Jatiya Samajtantrik Dal Hasanul Haq Inu and president of another faction of the Jatiya Samajtantrik Dal Moin Uddin Khan Badal, according to a party press release.A 16-member team, led by the Jatiya Oikya Front leader Kamal Hossain will join the talks. Senior BNP leaders including party secretary general Mirza Fakhrul Islam Alamgir are in the delegation.On 28 October, Kamal Hossain wrote to the prime minister for dialogue in order to hold the national election in a free and fair manner.The prime minister on 29 agreed to hold the dialogue and invited Kamal Hossain to join it at Ganabhaban.last_img read more

Ancient shrimp monster not so fierce after all

first_img This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only. Explore further Anomalocaris was a meter-long shrimp-like creature with lobed wings that lived around 500 million years ago. It is often illustrated in the act of devouring trilobites or other shelled animals, and has been dubbed the first “super predator” because of its supposed ability to swoop down and attack trilobites on the sea bed.Researchers from the Denver Museum of Nature and Science, led by paleontologist James “Whitey” Hagadorn, reconstructed the mouth parts of Anomalocaris by examining 400 fossils and selecting the best specimens and feeding their data into a 3D computer model. They also reconstructed 12 groups of trilobites of various kinds, modeling their shell strength on modern day lobster and crab shells. Hagadorn said the group tried to model the full range of shapes and sizes of prey and predator mouth parts.The computer model enabled them to test how much force the animal could generate with its bite. The results showed Anomalocaris’ armored mouth parts would break before adult trilobite shells did, the feelers were inflexible, and their mouths could not fully close. The fossils also suggested the teeth were actually flexible protrusions and the mouth parts were able to fold, which would not have been possible if their mouth parts were hard.Hagadorn said there was also no positive evidence of trilobite or other crushed shells within fossil feces or gut contents, and no evidence of the broken or chipped mouth parts that would be expected in a shell-crunching predator. The findings of the research suggest it was extremely unlikely Anomalocaris could have eaten most trilobites.Trilobite fossils have been found that appear to have scars or bite marks resembling Anomalocaris’ bite, but Hagadorn suggested the creatures possibly “ingested things and then spit them out,” but did not eat the trilobites.Hagadorn said the most likely diet of Anomalocaris was similar to that of modern arthropods such as crabs, lobsters and shrimps, which mostly eat soft items such as worms in the mud or microorganisms or plankton in the water. It could have eaten very small trilobites and recently molted trilobites whose new shells had not yet hardened, but the vast majority of trilobites would have broken Anomalocaris’ mouth parts.He stressed there is no positive evidence of Anomalocaris’ diet, but said this is not surprising because in the fossil record “mushed-up” worms, phytoplankton or snails are “all going to look like mush.”The results of the research were presented on 1 November at the annual meeting of the Geological Society of America in Denver, Colorado. (PhysOrg.com) — A Cambrian sea creature, Anomalocaris Canadensis, had long been thought to be a fearsome predator of trilobites, equipped as it was with barbed feelers and an armor-plated mouth, but new research suggests it was incapable of eating adult trilobites and probably survived by dining on “mush.” © 2010 PhysOrg.comcenter_img First great predator not much of one at all Citation: Ancient shrimp monster not so fierce after all (2010, November 4) retrieved 18 August 2019 from https://phys.org/news/2010-11-ancient-shrimp-monster-fierce.html Anomalocaris canadensis, the top predator from the middle Cambrian Burgess Shale of British Columbia, pencil drawing, digital coloring. The “tail fins” in this reconstruction should be placed ventrally (on top of the organism), and not at the rear as illustrated. Image: Nobu Tamura, via Wikipedia.last_img read more

Wake cloaking simulated in lab objects move through water without leaving a

first_img Explore further More information: Fluid flow control with transformation media, Yaroslav A. Urzhumov, David R. Smith, arXiv:1106.2282v1 [physics.flu-dyn] arxiv.org/abs/1106.2282AbstractWe introduce a new concept for the manipulation of fluid flow around three-dimensional bodies. Inspired by transformation optics, the concept is based on a mathematical idea of coordinate transformations, and physically implemented with anisotropic porous media permeable to the flow of fluids. In two different situations – for an impermeable object situated either in a free-flowing fluid or in a fluid-filled porous medium – we show that the object can be coated with a properly chosen inhomogeneous, anisotropic permeable medium, such as to preserve the streamlines of flow and the pressure distribution that would have existed in the absence of the object. The proposed fluid flow cloak completely eliminates any disturbance of the flow by the object, including the downstream wake. Consequently, the structure helps prevent the onset of turbulence by keeping the flow laminar even above the typical critical Reynolds number for the object of the same shape and size. The cloak also cancels the viscous drag force. This concept paves the way to energy-efficient, wake-free propulsion systems, which control and prevent wake formation through a smart spatial distribution of propulsion forces.via PhysicsWorld Citation: Wake cloaking simulated in lab – objects move through water without leaving a trace (2011, July 25) retrieved 18 August 2019 from https://phys.org/news/2011-07-cloaking-simulated-lab-.html Velocity pro le and streamlines of flow around and through the porous spherical shell surrounded by a viscous fluid. (See ref. below for details). Image credit: arXiv:1106.2282v1 This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only. © 2010 PhysOrg.com (PhysOrg.com) — Metamaterials researchers Yaroslav Urzhumov and David Smith, working at Duke University have built a simulation of an object that can move through water without leaving a trace and claim it’s a concept that could be built and used in the real world provided more research is done. In their paper, published on arXiv, the two describe how they programmed the use of metamaterials applied to an object, along with tiny water pumps, into a model to simulate an actual object moving through water without dragging some of the water with it that would normally cause turbulence. The two show, by use of a sphere, how an object could be covered with several layers of a mesh of wire or blades, from large ones nearest the object, too much smaller ones farthest away. The idea is to make up for the difference in movement between the object, and the stillness of the water it’s moving through, all while parting the water in ways gentle enough to cause cloaking and then allowing it to reseal after the object passes. The metamaterials provide the cloaking, while pumps are used to move the water at differing speeds in the different layers to keep the water from being dragged along as the object moves through it.The paper comes after what seems like one announcement after another in new cloaking technologies; first an invisibility cloak, then ones that cloaked sound, electric and ocean waves and even a time cloaking device; all are based on new so-called metamateriasl (materials with properties not found in nature).The advantages of the use of such technology are obvious; without drag, boats or submarines could go farther and faster while using less fuel, and if they ran nearly silent in doing so, it would herald the age of new stealth boats and ships that would be difficult if not impossible to detect by enemies looking for them. In the model created, the object was bullet sized and moves just a few millimeters per second, but the authors suggest that if an actual boat was to be made, it might make more sense to try to reduce just the drag, rather than try to hide the wake as well, as that would likely be much easier to actually make. The authors do not plan to try to build a real world boat, due they say, to lab constraints, but suggest a collaboration with another facility might be feasible. Next generation cloaking device demonstratedlast_img read more

The choice of mind

first_imgUnseen Passages, an art show that exhibits the works from the studios of two young and discerning women is on in the Capital that started off on 13 October. Delhi based artist Pallavi Singh’s series Desire to be Desired explores her observations of male vanity and the conditions that feed it. Punctuating the generation of the millennial is easier and faster access to information resulting in renewed socialisation and an increased interest in one’s self-image. Singh breaks away from the stereotype by focusing on the urban male to whom fashion and grooming are an important norm. A middle–aged potbellied bald man is her choice of protagonist, comically represented fussing over his physical appearance. The comment is intended to be both realistic and ironic, with Singh ensuring that the viewer steps aside from the work wearing a smile. Also Read – ‘Playing Jojo was emotionally exhausting’Soghra Khurasani’s from Baroda work is about freedom of thought and draws from a deep angst against unjust social and religious prescriptions. Her large-scale prints are compositions dominated by red: a colour that she feels expresses her rage and despair at the redundant injunctions imposed on common people. By morphing cells of blood into roses through valleys and volcanoes, her art posits the bittersweet moments. Khurasani’s current series Silent Landscapes reveals a resistance to violence and the telling impact of its trauma in rows, swirls and circles that inform the viewer of a never-ending cycle of repression and defiance.last_img read more

Gupta alleges AAP has scant regard for Assembly rules

first_imgThe Leader of Opposition in Delhi Assembly Vijender Gupta on Monday alleged that the AAP government is violating all rules and traditions in conducting the sessions of the Assembly and is running away from discussions.“This is the smallest session of the House. The government has confined the question hours to the last two days only. How can the budget be discussed in two days? The members will not get time to put their views,” said Vijender Gupta on Monday.  Also Read – Company director arrested for swindling Rs 345 croreHe alleged that the budget is scheduled to be presented on Friday, which was reserved for private member’s bills. “All the members should have been informed 12 days in advance about the session but it was not done,” added Gupta.As per the schedule of the Speaker the budget is likely to be presented in the House on Thursday, June 25.The Speaker, however, in a press conference informed that he had relaxed the norms for the question hour. “The question hours have been fixed for the last two days of the session. I have relaxed the norms to allow members to ask questions by relaxing the minimum limit of 12 days. So far 67 questions have been received,” said Ram Niwas Goel, the Speaker. Goel also informed that Friday is reserved for private member’s bill and three bills are scheduled to be introduced in the Assembly.last_img read more

Consumers Show Mixed Feelings About Housing Economy

first_img March 7, 2013 454 Views Consumers Show Mixed Feelings About Housing, Economy Agents & Brokers Attorneys & Title Companies Confidence Fannie Mae For-Sale Homes Home Prices Home Sales Housing Supply Investors Lenders & Servicers Mortgage Rates Processing 2013-03-07 Esther Cho In “”Fannie Mae’s””:http://www.fanniemae.com/portal/index.html most recent housing survey, consumers maintained their optimism toward home prices, while the share of consumers who said now is a good time to sell reached a record high. However, consumers in the survey were less optimistic about the economy and their own financial situation. [IMAGE]Nearly half, or 48 percent, of respondents in the February survey said they expect home prices to rise in the next 12 months, up from 45 percent in January. On average, consumers expect prices to rise by 2.9 percent over a year, up from 2.4 percent the month before. Seventy-three percent of respondents said now is a good time to buy, an increase from 69 percent the month before. At the same time, 25 percent also believe now is a good time to sell, the highest level since the survey’s June 2010 inception. “”Despite fiscal headwinds and political uncertainty, consumer sentiment toward housing is robust and continues to gather strength,”” said Doug Duncan, SVP and chief economist at Fannie Mae. “”We expect home prices to firm further amid a durable housing recovery, gradually reducing the population of underwater borrowers and helping to boost the share of consumers who say that now is a good time to sell.””[COLUMN_BREAK]Along with the increase in prices, more consumers also think mortgage rates will go up, with 44 percent of respondents expressing this view last month compared to 41 percent in January. Only 7 percent believe rates will go down. With the year-end HARP deadline looming ahead, Duncan explained rising rate expectations should prompt some borrowers to refinance soon to take advantage of more favorable mortgage terms. As a result, Duncan said this should “”add to their disposable income, helping to offset ongoing fiscal drag.””As for views on rent prices, 50 percent of consumer expects rent prices to go up in the next 12 months, unchanged from the month before and at the highest level since the survey began. A large majority of respondents, 67 percent, said they would buy if they were to move rather than rent, up from 65 percent the month before. When asked about the economy, 53 percent of respondents said the economy is on the wrong track, unchanged from January.Consumers were more pessimistic about their personal financial situation, with 41 percent believing it will get better, down from 43 percent the month before. More respondents said they think their financial situation will stay the same, with 41 percent of consumers expressing this view, up from 37 percent. The share of respondents who said their household income is significantly higher compared to a year ago decreased over the month to 21 percent from 23 percent. However, 31 percent said their expenses are significantly higher, down from 38 percent in January. Fannie Mae’s survey polled a representative sample of over 1,000 respondents.center_img in Data, Government, Origination, Secondary Market, Servicing Sharelast_img read more

March 10 2003 Plastering in the second floor unit

first_imgMarch 10, 2003Plastering in the second floor units of the East Crescent Complex continues. Construction crew member Jeff Buderer. [Photo: Jeff Kunzelman & Text: sa] [from left] Alumnus Angus Gluck has returned to instruct construction crew members Jeffrey Manta and Jeff Buderer in the intrecacies of plaster. [Photo: Jeff Kunzelman & Text: sa] Angus uses a long trawel to smoothen out the second coat of plaster [brown coat] on the ceiling of Unit 10. [Photo: Jeff Kunzelman & Text: sa] This is a hard job on the neck and arms. [Photo: Jeff Kunzelman & Text: sa] The crew finished the ceiling of Unit 10 with what is called a sponge float finish. It can be left as is or is rough enough if a third coat is desired. [Photo & Text: sa] The south-east wall of Unit 8 has received a third and finish coat. A finer milled plaster was used to achieve a very smooth finish. [Photo & Text: sa]last_img read more

April 9 2004 Congratulations to March 7 work

first_imgApril 9, 2004 Congratulations to March 7. workshop participants for completing their 5 week program today. >>top from left: Luigi Ciaccia, Jack Appelt, Sean Smith, Mark Baris, Dino Orsato, Guido Parigi and workshop coordinator Kelli Huth. >>middle from left: Chieko Shimizu, Takeshi Notsuki, Tomoya Shiota and Haruhisa Nakada. >>bottom from left: Jacob Schwartz, Ryoko Yamanaka, Maki Minakuchi and Takako Ueyama. [Photo & Text: sa]last_img

March 10 2008 We continue our series of reports a

first_imgMarch 10, 2008 We continue our series of reports about the installation of a set of solar panels that will provide power for lighting in the visitors parking lot and for the visitors path from the parking lot to the entrance of the visitors center. [See prior reports from 2/18 through 3/3/08]. The frame to hold the solar panels has been completed and utilities manager Scott Riley and crew Brendan Scott install the first panel. We continue our series of reports about the installation of a set of solar panels that will provide power for lighting in the visitors parking lot and for the visitors path from the parking lot to the entrance of the visitors center. [See prior reports from 2/18 through 3/3/08]. The frame to hold the solar panels has been completed and utilities manager Scott Riley and crew Brendan Scott install the first panel. [Photo: Amber Klatt & text: sa] Construction crew David Ledbetter and Brendan tighten the panels to the steel frame. The top of the Crafts III Visitors Center is visible in the background. Arizona State University, under the leadership of Program Manager William Shisler, has awarded Arcosanti this gift of solar panels from their Photovoltaic Testing Laboratory. [Photo: Scott Riley & text: sa] Our site electrician Dr. Sparks, in an interview with BigBug Canyon Country News reporter Bruce Colbert: “The real coup was getting the eight solar panels. Arizona State University Photovoltaic Testing Laboratory donated the solar panels to us. The ASU PTL tests the paenls for their wattage capacity, heat and humidity durability and basically put the panels through the wringer to see how they stand up, then they gave them to us.” We send a very big THANK YOU to William Shisler and the ASU Photovoltaic Testing Laboratory. Report continues on 3/13/08. [Photo & text: sa]last_img read more

BT is making 360º highlights and instant replays a

first_imgBT is making 360º highlights and instant replays available from a range of sporting events via the BT Sports App.Starting this week, viewers will be able to watch immersive highlights from the UEFA Champions League football match between Paris Saint-Germain and Bayern Munich.BT said it aims to show 360º footage from a minimum of 20 sporting events before June 2018 – including highlights from Champions League, Premier League and FA Cup football and World Title Boxing.The highlights and replays will be available alongside standard replays on the BT Sport App’s enhanced video player, which also allows viewers to select different camera angles and viewpoints.“This is another first for 360° broadcasting,” said Jamie Hindhaugh, chief operating officer, BT Sport. “It’s another step forward in broadcast innovation that will give BT Sport the best possible viewing experience and shows BT Sport continues its commitment to be at the heart of this.”“We’re passionate about sport and technology and want to continue to explore new ways to combine them for the benefit of our viewers and bring them closer to the action.”The launch comes after BT Sport first experimented with immersive content by showing the UEFA Champions League final through a number of 360°streams on YouTube and the BT Sport App earlier this year.last_img read more

Third Celsions LTSL technology promotes an accel

first_img Third, Celsion’s LTSL technology promotes an accelerated release of the drug when and where it will be most effective. That allows for direct targeting of organ-specific tumors. Celsion’s LTSL technology has shown that it’s capable of delivering drugs to the tumor site at concentrations up to 30 times greater than those achievable with chemotherapeutics alone, and three to five times greater than those of more traditional liposome-encapsulated drug-delivery systems. The company’s first drug under development is ThermoDox, which uses its breakthrough LTSL technology to encapsulate doxorubicin, a widely used chemotherapeutic agent that is already approved to treat a wide range of cancers. Currently, ThermoDox is undergoing a pivotal Phase III global clinical trial – denoted the “HEAT study” – for the treatment of primary liver cancer (hepatocellular carcinoma, or HCC), in combination with radiofrequency ablation (RFA). RFA uses high-frequency radio waves to generate a high temperature that is applied with a probe placed directly in the tumor, which by itself kills tumor cells in the immediate vicinity of the probe. Cells on the outer margins of larger tumors may survive, however, because temperatures in the surrounding area are not high enough to destroy them. But the temperatures are high enough to activate Celsion’s LTSL technology. Thus, the heat from the radio-frequency device thermally activates the liposomes in ThermoDox in and around the periphery of the tumor, releasing the encapsulated doxorubicin to kill remaining viable cancer cells throughout the region, all the way to the tumor margin. ThermoDox is also undergoing a Phase I/II clinical trial for the treatment of recurrent chest wall (RCW) breast cancer (known as the “DIGNITY study”), and a Phase II clinical trial for the treatment of colorectal liver metastases (the “ABLATE study”). But most of the drug’s (and hence the company’s) value is tied up in the HEAT study. The HEAT trial is a pivotal 700-patient global Phase III study being conducted at 79 clinical sites under a special protocol assessment (SPA) agreement with the FDA. The FDA has designated the HEAT study as a fast-track development program, which provides for expedited regulatory review; and it has granted orphan-drug status to ThermoDox for the treatment of HCC, providing seven years of market exclusivity following FDA approval. Furthermore, other major regulatory agencies, including the European Medicines Agency (EMA) and China’s equivalent, have all agreed to use the results of the HEAT study as an acceptable basis to approve ThermoDox. The primary endpoint for the HEAT study is progression-free survival – living longer with no cancer growth. There’s a secondary confirmatory endpoint of overall survival, too. Both the oncological and investing community are eagerly awaiting the results, which are due any day now. So then, why are we on the sidelines now, right when the big news is due to hit? That all goes back to why Celsion was such a good investment to begin with, and what it can tell us about finding other big wins in the technology stock market. A Winner in the Making When we’re looking for a strong pick in the biotechnology, pharmaceuticals, and medical devices fields – once we have established the quality of the technology itself and ensured it will likely work as expected – there is a simple set of tests we apply to ensure that we’ve found a stock that can deliver significant, near-term upside. The most critical of these are: The technology must provide a distinct competitive advantage over the current standard of care and be superior to any competitors’ effort that will come to market before or shortly after our subject’s does. In other words, it must improve outcomes, by improving patients’ length or quality of life (i.e., a cure for a disease, or a maintenance medication with fewer side effects), or lower costs while maintaining quality of care (i.e., a generic drug). A therapy that does both is all the better. There must a clear path to market in the short term, or another catalyst to propel the stock upward. An investment in a great technology does not always make for a great investment. You have to consider the quality of the management team and structure of the company, including its ability to pay the bills and get to market without defaulting or diluting you out of your positions. And of course, time. The biggest and most frequent mistake investors make in technology is assuming that it is smooth and short sailing from concept to market. Reality is much harsher than that, and in biotechnology and pharmaceuticals in particular – with a tough regulatory gamut to run – the timeline to take a new technology to market can be anywhere from a decade to thirty, forty, or even fifty years. Liposomes are a perfect example of that. Twenty years ago, I probably could have told you a story about a technology that was very similar to what was laid out above. It would be compelling and enticing to investors of all stripes – a breakthrough technology with the promise to revolutionize cancer care by making chemo less toxic and more effective at the same time. Yet had you invested in that promise alone, chances are you’d be completely wiped out by now, or maybe – just maybe – still waiting for a return. That is why we invest in proof, not promises. So, how does Celsion stack up against our four main proof points? Time to market: When we first recommended Celsion, it was in Phase III pivotal trials. This is the last major stage of human testing usually required before a company can submit an FDA New Drug Application and apply to market the product. The process of bringing a drug to market, even once a specific compound has been identified and proven to work in vitro (in the lab), is perilous. Many things can go wrong along the way. If you look at investing in a company whose drugs are just entering Phase I clinical trials, for instance, it is still unclear if the therapy is effective in vivo (in the human body). This is a critical stumbling block for many companies, whose promising compounds immediately prove less effective or more dangerous than testing suggested. Even if Phase I goes well, it can take up to a decade and sometimes longer to get from there to market with a drug. And then, even Phase II trials often leave treatments five or more years from market – though there are exceptions in cases where a therapy is proven very effective or a disease has so few treatment options available. But shortcuts are rare, and investors have to consider the time and expense (which leads to fundraising and ultimately dilutes your return) of getting from A to Z. In this regard, Celsion made a uniquely great investment. When we first recommended the company, it was in the midst of a pivotal Phase III trial and looked to be about a year or so away from its first commercialization. (Though, speaking to the length of these trials, this one had been started back in 2008.) With many of the most high-profile companies in the industry – those working on vogue treatment areas and conditions, like hepatitis C treatments of late – when they get this close to market, the large banks bid up stocks to high levels, content to squeeze just a few percentage points out at the end. They have to be conservative, since they’re investing large amounts of other people’s money. However, biotechnology is such a fragmented space with far more companies than Wall Street can possibly cover in depth, that coming across a gem like Celsion late in the game with a potentially big win is not as uncommon as you’d think. The “efficient market” hypothesis fails to account for the fact that no one can know everything, including every stock. And Celsion had gone all but unnoticed for some time. Payer acceptability: Celsion has the benefit of developing a 2.0-style product, an improvement over something that already exists. RFA is already in relatively widespread use and has proven effective enough that most every insurance and benefits provider will cover it. Even the early generations of LTSL, while not quite as safe or effective as desired, were enough of a benefit to gather pretty solid support from payers. Celsion, through its clinical trial process, has proven its unique blend is safer, better tolerated by patients, and much more effective than its predecessors. Thus, payer support at a reasonable price is a pretty sure bet. Market size: When we originally recommended Celsion, we stated that the company was sitting on a multibillion-dollar opportunity. And we stand by that statement. However, just because something is eventually worth that amount does not mean it’s bankable today as a short-term investment. So we try to keep our analysis narrowly focused on what can be directly counted on and measured. In Celsion’s case, that’s the Phase III treatment, Thermodox, and the one area in which it is being studied: primary liver cancer (HCC). Even just in this narrow band, however, we see the market opportunity for Celsion as in excess of $1 billion. HCC is one of the most deadly forms of cancer. It currently ranks as the fifth most-common solid tumor cancer, and it’s quickly moving up. With the fastest rate of growth among all cancer types, HCC projects to be the most prevalent form of cancer by 2020. The incidence of primary liver cancer is nearly 30,000 cases per year in the US, and approximately 40,000 cases per year in Europe. But the situation worldwide is far worse, with HCC growing at approximately 750,000 cases per year, due to the high prevalence of hepatitis B and C in developing countries. If caught early, the standard first-line treatment for primary liver cancer is surgical resection of the tumor. Early-stage liver cancer generally has few symptoms, however, so when the disease is finally detected, the tumor is usually too large for surgery. Thus, at least 80% of patients are ineligible for surgery or transplantation by the time they are diagnosed. And there are few nonsurgical therapeutic treatment options available, as radiation and chemotherapy are largely ineffective. RFA has emerged as the standard of care for non-resectable liver tumors, but it has limitations. The treatment becomes less effective for larger tumors, as local recurrence rates after RFA directly correlate to the size of the tumor. (As noted earlier, RFA often fails at the margins.) ThermoDox promises the ability to reduce the recurrence rate in HCC patients when used in combination with RFA. If it proves itself in Phase III, there’s no doubt the drug will be broadly adopted throughout the world once it is approved. A quick look at the numbers: According to the most recent data from the National Cancer Institute, the incidence rates of HCC per 100,000 people in the three major markets are 4 in the US, 5 in Europe, and approximately 27 in China. Based on these incidence rates, the total addressable market in these three regions (which we will conservatively assume to be the total addressable worldwide population for the time being) is approximately 400,000 (12,000 in the US, 40,000 in Europe, and 351,000 in China). Assuming that 50% of HCC patients are eligible for nonsurgical invasive therapy such as RFA, approximately 200,000 patients worldwide would be eligible for ThermoDox. Further assuming an annual cost of treatment for ThermoDox of $20,000 in the US, $15,000 in Europe, and $5,000 in China, in line with similar treatments of the same variety, we estimate that the market potential of ThermoDox could be up to $1.3 billion. Not to mention the countless thousands of lives saved. (And that’s before the rest of the developing world comes online.) Of course, this is an estimate of ThermoDox’s potential assuming 100% market penetration – something that simply never happens. While we expect ThermoDox in combination with RFA to become the standard of care for primary liver cancer, a more reasonable expectation for maximum market penetration after a six-year ramp-up to peak sales (from an expected approval in 2013) is probably 40%. Improving outcomes or lowering costs: This is exactly what the Phase III trial was intended to prove: efficacy beyond a shadow of a doubt. Given preliminary data and earlier trial results, it was already a pretty sure thing, so in our model, we assumed about a 70% chance of success (to be on the conservative side, as always – it’s better to be right by a mile than to miss by an inch). Once we incorporate that probability of success into our model, we come to a probability-weighted peak sales figure in 2019 of approximately $365,000,000 annually. The average-price-to-sales ratio among the big players in biotech these days is about 5. If we apply a sales multiple of 3 (i.e., just 60% of the average) to Celsion’s probability-weighted peak sales for ThermoDox in 2019, we come up with a value for the company of nearly $1.1 billion, which would equate to about $33 per share if it did not issue any new stock between now and then – that’s more than 17 times where the stock was trading when we recommended a buy. And remember, these numbers are only for ThermoDox under the HCC indication. Our Move to the Sidelines With final data from the current Phase III pivotal trial due expected to come in within the next few weeks, Celsion’s stock has ballooned in value from the $2 range to $7.50 or so in the past few weeks. Now, that’s a far cry from the $33 price we mentioned above, but remember, that’s a target for 2019. And it doesn’t allow for a whole range of things that could go wrong. Chief among those concerns is that the Phase III data come in more poorly than expected. Even just a small variance in efficacy or a simple question about safety can knock a few hundred million dollars off those sales figures. Or it can push trials back a year or two, delaying returns and sending short-term-minded investors, like those who have recently bid up CLSN shares, retreating to the hills for the time being. Further downfield there is sure to be competition as well, and of course we may get those miraculous chemo-free treatments mentioned up front. In short, we don’t have a crystal ball and can’t tell you what the world will look like in 2019. If you believe yours is clear, ask yourself if you thought touchscreen phones and tablets would outsell traditional computers by 3 to 1 globally in 2012. If not, you might want to give the crystal a polish. To be clear, the value of Celsion in the near term hinges on a binary event – the results of the ongoing HEAT trial. We are of the opinion that CLSN represents one of the best opportunities we’ve come across since we started this letter, and that the probability of a successful trial is high. Nevertheless, there is substantial down side if the trial is unsuccessful. And it could take years to recover, if ever, on news of a delay from any concerns raised. We’d already advised subscribers to take a free ride early on in our coverage of the stock, taking all of the original investment risk away. However, even with that protection, the short-term potential is still more heavily weighted to the down side. Thus, we booked our profits and stepped to the sidelines on this one. Celsion continues to be a model, even at today’s prices, for a great biotech investment with significant upside potential. But we’re content to wait for the market to hand us another, similar opportunity. The pages of Casey Extraordinary Technology are filled with investments just like Celsion – up-and-coming technology companies the market has yet to discover. Subscribe today and save 25% off the regular price, as always backed by our unconditional money-back guarantee. Bits & Bytes More 3D-Printer Magic (Gizmag) Last week, we noted some of the cool things people are doing with 3D printers. But it’s hard to keep up. The tech is blasting ahead so fast that this week we couldn’t resist adding another. Researchers at the University of Warwick, already known for its cutting-edge tech research, have created a cheap, plastic composite that can be used even with low-end 3D printers to produce custom-made electronic devices. The potential here is staggering. Tablets – Hotter than We Thought (Computerworld) Global market-research company IDC has revised its estimate for sales of tablets for 2012 upward by 4.5%, to 122.3 million units. Apple is expected to lose market share to surging Android-based devices. Whose Internet Is It? (GamePolitics) Well, the US Congress appears to think it’s the people’s. Other countries disagree, and have been trying to wrest control of the ‘Net from our hands for a while now. Many want the UN in charge. But this week, the House unanimously passed a Senate resolution calling on the US government to officially oppose any transfer of Net control to the UN. We’d guess this battle is far from over, though. Tattoo You? (Gizmag) Next time you see a runner with a smiley-face tattoo on his or her arm, you might be looking at a sophisticated metabolic sensor, designed to detect stress due to exertion. Of course, we aren’t always in a smiley frame of mind, are we? So if we could just cross one of these things with a mood ring… We are not ones for bragging about our accomplishments. Whether you believe in such mystical forces as karma or not, it’s generally a good rule that those who take too much credit for their successes are soon rewarded with a streak of the opposite, just to keep them humble. However, it is just as important to take stock in your achievements as it is your failures, if you are going to learn and grow as an investor (or in any pursuit). As such, this week I want to introduce you to the story of a company that we recommended to our investment advisory subscribers back in April 2012. It’s since gone on to gain significantly. The stock rose 297% from our initial recommendation to the day the “sell” call was made. What’s important about this small company is why it made our investment list to begin with, and what its characteristics can tell us about successful speculation in the arena of up-and-coming technology companies. Sincerely, Alex Daley Chief Technology Investment Strategist Casey Research Anatomy of Great Technology Investment By Alex Daley, Chief Technology Investment Strategist Traditional cancer treatment options are little more than a crude mix of “slash, burn, and poison” – that is surgery, radiation, and chemotherapy. There are radical new treatments in labs and trials all over the world that promise to throw out this trifecta; no other disease has received more of the research interest and funding that have defined modern biotechnology over the past three decades. I’m not going to tell you about any of those here. Sure, many of them will be wildly successful and make many investors fabulously wealthy over the next few decades. But most will fail. And those that don’t will take a long time to turn a profit for investors. Yet, there is one small company whose unique twist on cancer treatment is proving to be a major upgrade. We profiled this company in a recent edition of Casey Extraordinary Technology, and it turned in a gain of over 167% for subscribers in just six months’ time. It may yet make billions more still for investors. You see, in recent years chemotherapy has become the core treatment for most cancerous malignancies. And while these toxic cocktails of chemicals have proven effective at destroying cancerous cells, they also have one problem. A big one. Chemo, being essentially a poison, doesn’t just attack cancerous cells – it attacks a broad range of healthy cells too. As a result, the treatment can sometimes be as harmful as the cancer itself in the short run. The side effects are awful, and its use can quickly erode patients’ health. Some have even described chemo as a “cure that’s worse than the disease.” This sad state of affairs for the world’s second most-prevalent chronic disease is why the cancer-research arena has been exploding over the past few years with the goal of developing more targeted, less-toxic therapies – in other words, to do a better job killing cancer cells while leaving healthy cells alone. That’s exactly what Lawrenceville, New Jersey-based Celsion Corp. (CLSN) has the technology to do. And chances are the company is on to one of the biggest cancer-treatment breakthroughs in decades. How It Works Our story starts with liposomes. These nanosized artificial vesicles are made from the same material as our cell membranes – natural phospholipids, i.e., a version of the chemicals that make up everything from fat to earwax, and cholesterol. Not long after their discovery in the 1960s, scientists began experimenting with liposomes as a means of encapsulating drugs, especially cancer drugs. Why? Something called the “enhanced permeability and retention” (EPR) effect. This is a property of certain sizes of molecules – for example, liposomes, nanoparticles, and macromolecular drugs – which tend to accumulate in tumor tissue much more than they do in normal tissues. It’s a useful feature for a cancer drug. Thus, they offer a potential way to combat the two biggest drawbacks of traditional chemotherapeutics: systemic toxicity and low bioavailability at the tumor site. In other words, the drugs now employed are themselves are toxic to normal cells, and they tend to get largely used up before they even reach the tumor site. Early attempts to encapsulate drugs inside liposomes did an okay job of dealing with the toxicity issue, but bioavailability at the tumor site was still limited. Our immune system saw to that. Just like virtually anything else artificial we put into our bodies, traditional liposomes were seen as invaders. Thus, they were rapidly cleared by the mononuclear phagocyte system, the part of the immune system centered around the spleen (yes, we do use it) that destroys viruses, fungi, and other foreign invaders. However, a breakthrough arrived when scientists came up with a new way to sneak these artificial compounds into the body undetected by our defenses. The process gave us what are call “PEGylated” liposomes, with a covalent attachment of polyethylene glycol polymer chains. The effect of attaching these little plastic chains to the end of the liposome was to create a “stealth” liposome-encapsulated drug that was hardly noticed by the system. Problem solved, right? Well, not exactly. A lot of hard work went into getting drugs into liposomes to reduce toxicity, then a bunch more into stopping our immune system from kicking in. But there was still yet another problem. The drug-release rates of these stealth liposomes were generally so low that tumor cells barely got a dose. Scientist had made them so stealthy that they even skated right by cancer cells, usually failing to kill off the tumors. After decades of experimenting with liposome-encapsulated cancer drugs, scientists still had not been able to safely deliver therapeutic concentrations of the chemotherapy drugs to all tumor cells. They had to devise a way to induce drug release when and where it would be more effective. The next big idea came in more recent years, as scientists devised temperature-sensitive liposomes. Heat them and they pop, releasing the drugs just when you need them to. From stealth to non-stealth in a matter of seconds, and right on target. Fortunately, they were able to make it work, but unfortunately, not at temperatures that didn’t essentially cook patients from the inside – sort of defeating the purpose of keeping the chemo at bay to reduce collateral damage. They failed to perform at tolerable levels of heat or time. Fifteen minutes of baking and still only 40% or so of the drug was released, and it took temperatures up to 112° Fahrenheit. It might not sound like much, but it was enough to be intensely painful and damaging as well. That’s where Celsion came in. It’s designed and developed a novel form of these temperature-sensitive chemo sacks – the first of their kind to work effectively and safely – otherwise known as a lysolipid thermally sensitive liposome (LTSL). Celsion’s liposomes are engineered to release their contents between 39-42° C, or 102.2-107.6° F (thus, another translation of LTSL has become “low-temperature sensitive liposome”). And they release the contents at an extremely fast rate, to boot. A Better Way to Use Chemo These unique properties of Celsion’s LTSL technology make it vastly superior to previous liposome technology for a number of reasons. For starters, the temperature range is much more tolerable to patients and won’t injure normal tissue. Payers should be easily convinced to cover the new therapy at profitable rates. In the modern world of health care, failure of a treatment to garner coverage from government medical programs like Medicare and the UK Health Service, and private insurance companies (which generally cooperate closely to decide how to classify and whether to cover a treatment) is usually a game-ender. Payers have a responsibility not just to patients but to their shareholders or taxpayers to stay financially solvent. This means that if a therapy does not provide a compelling cost/benefit ratio, then it won’t be covered. For instance, if you release a new painkiller that is only as effective as Tylenol and costs $1,000 per dose, you’re obviously not going to see support.center_img Second, the temperature range takes advantage of the natural effect mild hyperthermia has on tumor vasculature. Numerous studies have shown that temperatures between 39-43° C increase blood flow and vascular permeability (or leakiness) of a tumor, which is ideal for drug delivery since the cancer-killing chemicals have easy access to all areas of the tumor. These effects are not seen at temperatures below this threshold, and temperatures above it tend to result in hemorrhage, which may reduce or cease blood flow, hampering drug delivery. It’s the Goldilocks Effect: The in-between range is perfect. The market must be measurable and addressable. There must be some way to say specifically how many patients would benefit from a therapy, and to ensure that those patients have providers caring for them that would make efficient distribution of the therapy possible. For instance, a successful treatment for Parkinson’s disease might be applicable to hundreds of thousands of patients, with little competition from other treatments, whereas a treatment for Von Hippel-Lindau (VHL) might only reach hundreds. If the goal is to recover years of research investment and profit above and beyond that, then market size matters, as do current and future competitors that might limit your reach within a treatment area.last_img read more

Were beginning to approach oversold territory and

first_img We’re beginning to approach oversold territory and, as you probably already know, how soon we get to those lows will depend on how quickly the powers-that-be take the remaining slices.  A re-read of Ted’s quote above would be useful at this point. And as I type this paragraph, the London open is just under ten minutes away.  Gold, platinum and palladium prices are unchanged—and silver is up a nickel.  Gold’s net volume is very light at just under 11,500 contracts—virtually all of it of the HFT variety—and silver’s net volume is around 4,200 contracts, with decent roll-overs out of July already.  And after rallying about 20 basis points in the early going in Hong Kong trading on their Friday morning, the dollar index is back to unchanged.  Without doubt, all eyes will be on the job numbers this morning in New York—and what trading ‘action’ will accompany their release. Of course the job numbers should make no difference to the gold price at all, but a long history shows that JPMorgan et al use that as an excuse on many occasions to drive the precious metal prices into the dirt—and I’ll be amazed if that doesn’t happen this morning. Today we get the Commitment of Traders Report for positions held at the close of COMEX trading on Tuesday—and I doubt if we’ll see much, if any, improvement in the Commercial net short positions in either gold or silver, as the reporting week was pretty flat from a price perspective.  All the price action that mattered most didn’t start until the day after the cut-off—and it’s a very safe bet that it was no accident that it happened this way, as “da boyz” have used this trick for at least a decade when they want to hide their tracks for as long as possible. We also get the companion Bank Participation Report as well.  This is data that’s extracted directly from the COT Report—and shows what the world’s banks have been up to during the month that was and, as I always say at this juncture, they’re usually up to quite a bit.  I’ll have all that data in my Saturday column. And as I send the Friday edition of today’s column out the door at 5:25 a.m. EDT, I see that gold began to develop a slight negative bias starting at 2 p.m. Hong Kong time on their Friday afternoon. Ditto for silver.  Gold is down a couple of bucks, but silver is still up a nickel.  Platinum and palladium are trading flat. Gold’s net volume is now a bit over 22,000 contracts—and silver’s net volume is pretty decent as well at 6,500 contracts, but there’s been no increase in roll-over activity from over two hours ago. The dollar index was slowly heading south, but has recovered a bit in the last half hour—and is currently down only 3 basis points. As I said above, all eyes will be on the 8:30 a.m. EDT jobs report—and if you’re feeling a bit like that poor chap in the last cartoon posted above, I’ll certainly understand—as I feel that way myself at the moment. Enjoy your weekend, or what’s left of it if you live west of the International Date Line—and I’ll see you here tomorrow. Here’s the 5-minute gold tick chart courtesy of Brad Robertson.  As you can tell by the volume spikes, “da boyz” stuck it to the Managed Money traders real good once again during the COMEX trading session.  Midnight Wednesday is the vertical gray line—and you have to add two hours for EDT—and the ‘click to enlarge’ feature is a must. The silver chart was similar to gold’s, right up until 3:30 p.m. in the New York Access market.  At that point a willing seller stepped in and ensured that silver closed on its absolute low tick of the day. The high and low ticks were reported by the CME Group as $16.50 and $16.065 in the July contract. Silver finished the Thursday session at $16.075 spot, down 40 cents on the day.  Gross volume was very decent, as was net volume—46,000 contracts. Avrupa and Antofagasta intersect copper-rich VMS in Pyrite Belt, Portugal •             First Greenfields discovery of massive sulfide mineralization in 20 years in the Iberian Pyrite Belt •             10.85 meters of massive and semi-massive/stockwork sulfide mineralization grading 1.81% Cu, 2.57% Pb, 4.38% Zn, 0.13% Sn, and 75.27 ppm Ag •             Including 7.95 meters @ 2.21% Cu, 3.05% Pb, 4.82% Zn, 0.15% Sn, 89.8 ppm Ag •             Followed by 2.90 meters @ 0.71% Cu, 1.27% Pb, 3.17% Zn, 0.092% Sn, 35.4 ppm Ag •             Avrupa and Antofagasta sign an amended Joint Venture Agreement Please visit our website to learn more about the company and current exploration program. Platinum prices were a mini version of the gold price chart—and palladium was a mini version of the platinum chart.  Platinum closed on Thursday at $1,098 spot, down three bucks, finally cracking the $1,100 spot price to the downside.  Palladium also closed 3 dollars lower at $753 spot.  Here are the charts. The CME Daily Delivery Report for Day 5 of the June delivery month showed that zero gold and 9 silver contracts were posted for delivery within the COMEX-approved depositories on Monday.  Nothing to see here. The CME Preliminary Report for the Thursday trading session showed that gold open interest for June dropped another 282 contracts, leaving 1,262 still open.  June o.i. in silver was up 7 contracts to 40. There was no reported change in GLD, but another deposit was made in SLV.  This time it was 1,433,379 troy ounces.  So far this week, there has been a bit over 2.5 million ounces deposited in SLV.  Since the price action indicates that silver should be flowing out of that ETF, the deposits must have been used to cover an existing short position.  We’ll have to wait until about June 23 when the next short position report comes out of the folks over at shortsqueeze.com in order to get a hint of what might be going on. Since yesterday was Thursday, Joshua Gibbons, the Guru of the SLV Bar List, updated his website with the goings-on over at the iShares.com Internet site at the close of trading on Wednesday—and this is what he had to report. “Analysis of the 03 June 2015 bar list, and comparison to the previous week’s list:  1,138,121.2 troy were added (all to Brinks London), 893,539.6 oz were removed (all from Brinks London), and 113 bars had serial number changes.” “The bars removed were from: Solar Applied Materials (0.3M oz, Krasnoyarsk (0.2M oz), and 10 others.  The bars added were from: Krasnoyarsk (0.2M oz), Prioksky (0.1M oz), and 13 others. “As of the time that the bar list was produced, it was overallocated 384.9 oz.  All daily changes are reflected on the bar list.” Over at Switzerland’s Zürcher Kantonalbank for the week ending May 29—they reported tiny declines in both their gold and silver ETFs.  Their gold ETF shed 1,804 troy ounces—and their silver ETF dropped only 7,123 troy ounces. After four straight day of sales, it should come as no surprise that there was no report from the U.S. Mint yesterday. Over at the COMEX-approved depositories on Wednesday, there was 50,092 troy ounces of gold transferred from Canada’s Scotiabank to HSBC USA.  Other than that, there was no activity worth mentioning, but the link to what there was, is here. It was another huge in/out day in silver, as 411,788 troy ounces were received—all at JPMorgan’s vault—and 1,012,058 troy ounces were shipped out.  All of the ‘out’ movement was from Canada’s Scotiabank, including the 411,788 troy ounces that JPMorgan received.  The link to that action is here—and it’s worth a quick look. There wasn’t a lot of activity at the COMEX-approved gold kilobar depositories in Hong Kong on their Wednesday, as only 775 kilobars were reported received—and another 475 were shipped out.  All of the action was at Brink’s, Inc. as usual.  The link to that activity is here. I have a fair number of stories for you today—and I’ll happily leave the final edit up to you. Since we penetrated for the first time to the downside the key 50-day moving average in silver on Wednesday, I suppose the official price take-down cycle is now in effect. Gold, you’ll remember, had penetrated its 50-day moving average a week or so ago, so the market structure there is more advanced than it is in silver. Therefore, in silver, it’s more a question of how many contracts the commercials can induce the managed money traders to sell than it is how low prices must fall. It’s more about contracts sold than prices, although successive lower prices (salami slicing) are necessary to effect the full contract count outcome. In other words, it’s not necessary that we drop dramatically in price, just enough—and in the manner necessary to accomplish whatever complete managed money selling results this go around. Of course, please dismiss any suggestion that I (or anyone else) know for sure the direction of prices in the short term. This is about probabilities based upon the same thing that those probabilities have always been based on – past and prospective COT patterns. And even though those probabilities suggest lower silver prices ahead, any such decline should prove minor compared to the eventual much higher prices that the actual fundamentals and facts point to. While I hope my COT analysis is beneficial, please understand it is not my intent to handicap silver prices in the short term, although many others do seem so engaged. Instead, my intent is to use my analysis of the COT market structure to show just how screwed up is the price discovery process on the COMEX and, after 30 years, it is encouraging to see that at least one silver miner may feel the same. In the unfortunate circumstance that the probabilities once again prove correct and we do witness further declines in the price of silver, perhaps that might aid in convincing other silver producers to step up to the plate and write to the CFTC. Trying to come up with rational explanations for why silver and gold prices behave as they do, while leaving out the COT market structure on the COMEX, is guaranteed to reduce one to the babbling idiot level. —  Silver analyst Ted Butler: 05 June 2015 Another day—and more salami slicing in the all four precious metals, particularly gold and silver.  There was decent volume associated with both metals, so it’s an absolute certainty that the Managed Money was puking longs and piling on the short side, while JPMorgan et al gobbled up everything on the opposite side of those trades for fun, profit and price management purposes.  And it was a very profitable day for “da boyz” yesterday. Here are the 6-month charts for all four precious metals—and new lows were engineered in three of the four precious metals. The gold stocks opened down—and chopped more or less sideways for the remainder of the day, as the HUI closed down another 1.35 percent. It was more or less the same thing in the silver equities, although the trading day had more shape to it.  The big drop because someone sold a boat load of shares in Peñoles right at the close, at least that’s what Nick said yesterday when I asked him.  Because of that, Nick’s Silver Sentiment Index got hit for 2.26 percent.  Without that share dump, the loss would have been about 0.5 percent. Without doubt, all eyes will be on the job numbers this morning The gold price chopped around, mostly lower, during the Far East trading session on their Thursday—and both the rally attempt in the Far East—and the one in early London trading, met with a resolute seller the moment that the price attempted to break above unchanged.  JPMorgan et al, HFT algorithms in hand, did the dirty starting the moment that COMEX trading began—and by around 11:20 a.m. EDT, their work was done for the day, with another low for this move down.  The gold price rallied quietly after that, before chopping sideways starting around 2:40 p.m. in electronic trading. The high and low tick were recorded as $1,186.60 and $1,172.40 in the August contract. The gold price closed in New York yesterday at $1,176.40 spot, down another $8.60 from Wednesday’s close.  Net volume was very decent at 148,000 contracts. Here’s the 6-month U.S. Dollar chart as a reference. The dollar index finished the Wednesday trading session in New York at 95.37—and traded virtually ruler flat until about 1:30 p.m. Hong Kong time.  At that juncture it rallied 20 basis points, hitting 95.56 at 8:30 a.m. BST in London trading.  It fell of a cliff at 9 a.m. right on the button, hitting its 94.72 low about thirty five minutes later.  Then at noon BST it appeared that ‘gentle hands’ showed up—and the dollar rallied to a handful of basis points above unchanged minutes before trading began in the equity markets in New York.  It rallied higher from there in a rather choppy manner—and closed yesterday at 95.58—up 21 basis points from Wednesday. It’s obvious to me that the dollar would crash if given the opportunity to do so—and it’s equally as obvious that the powers-that-be are at hand to prevent that from happening.last_img read more

People with HIV have been failed by the government

first_imgPeople with HIV have been failed by the government’s new disability benefit, according to new research.The research by the National AIDS Trust (NAT) found that only three-fifths of people living with HIV were found eligible for the new personal independence payment (PIP) after being reassessed.NAT says its research has confirmed long-standing fears that people with HIV would not receive the support they needed under PIP, which is supposed to help cover people’s extra disability-related costs.Its report shows that only three-fifths (63 per cent) of the 1,000 people with HIV who were previously receiving disability living allowance (DLA) and had been reassessed for PIP were awarded the new benefit.This compares with 73 per cent of all DLA claimants who had been reassessed and were awarded PIP, according to the figures, published by the Department for Work and Pensions (DWP) last December.One charity that works with NAT, River House, described yesterday (Wednesday) how a 57-year-old man who was diagnosed last October with HIV and also had chronic obstructive pulmonary disease, had been awarded zero points after a PIP assessment in April.An appeal to the Department for Work and Pensions (DWP) – the so-called mandatory reconsideration stage – was refused in late June.By this time, his health had deteriorated even further and he was admitted to hospital, where he was diagnosed with untreatable lung cancer.He was due to receive DWP’s decision on a fresh PIP application this week, but died on Monday morning.Another River House service-user with HIV has described how he had to start using foodbanks after his PIP was suddenly stopped because he missed a renewal deadline by just two days after he was diagnosed with cancer.DWP refused to reconsider removing his PIP and he had to wait more than 16 weeks to be assessed again.He said: “From the moment that my PIP stopped, I lost the uplift in my ESA [employment and support allowance] that I received because I was now not receiving PIP.“While I waited to be assessed for PIP and again for ESA, I had to borrow small amounts of money from friends [and] organisations that support people living with HIV and I was a regular visitor to local food banks.”The NAT analysis also shows that people with HIV who had been claiming DLA were more likely (43 per cent) than the average DLA claimant (30 per cent) to see their level of support cut if they were awarded PIP after a reassessment.According to last December’s figures, only about 1,000 of the 7,920 people living with HIV who were claiming DLA at the start of the PIP rollout in 2013 – which itself was about 10 per cent of all those with HIV in the UK – had been reassessed.The charity says that not everyone living with HIV in the UK has benefitted equally from modern treatments – for example, long-term survivors and people diagnosed late – and some will have life-long health problems as a result of HIV. One study found that two-thirds of people living with HIV in the UK have at least one other condition, in addition to HIV, and 38 per cent have more than one additional condition.Deborah Gold, NAT’s chief executive, said: “The evidence so far is that PIP is not working for people living with HIV who need extra support.“The assessment is not fit for its stated purpose, to identify the disability-related barriers to participation and independence experienced by people living with HIV. “The tick-box eligibility criteria describe only the most basic aspects of existence, such as physical capacity to consume food and bathe, without any understanding of the social context of life with a serious long-term condition.”Among the charity’s many concerns about the assessment process are that it fails to accurately capture: the risk of isolation due to HIV-related anxiety; the need for support with nutrition; and the importance of adhering to HIV medication.Sarah Radcliffe, NAT’s director of policy and campaigns, said that the research – the first to be carried out into the impact of PIP on people with HIV – shows that the concerns raised when the abolition of working-age DLA was announced in 2010 were not baseless.She said the way the assessment was devised “means people living with HIV will not have their support needs identified – or where they are picked up, this will not necessarily translate to support”.And she said the social model “rhetoric” used by DWP when it introduced the new benefit – focussing on how social factors create barriers to participation for disabled people – “has not translated to reality for PIP”.Instead, she said, the PIP assessment “looks a lot like the work capability assessment’s notorious ‘tick box’ medical approach”.She added: “The descriptors used are proxies for a basic existence and not for barriers to participation or the extra costs associated with an active, independent life.“It is not too late to improve PIP for people living with HIV. The vast majority are yet to be reassessed.  “It is time to look again at PIP, from scratch, and make sure it lives up to its stated goals of promoting participation and independence.”A DWP spokeswoman said in a statement: “We introduced PIP to replace the outdated DLA system – it takes a much wider look at the way someone’s health condition or disability impacts them on a daily basis and is tailored to suit each individual’s needs.“Decisions are made following consideration of all the information provided by the claimant, including supporting evidence from their GP or medical specialist.“Under PIP, 28 per cent of claimants are now receiving the highest rate of support, compared to 15 per cent under DLA, and anyone who disagrees with a PIP decision has the right to appeal.”But DWP figures from last December also showed that fewer than half (about 126,000) of the 254,000 people previously receiving the higher rate mobility component of DLA secured the same level of mobility support when reassessed for PIP.And unpublished DWP figures obtained by DNS in March showed nearly half of disabled people subject to “planned reviews” of their eligibility for PIP were having their existing award either cut or removed completely.NAT has produced free resources on PIP for people living with HIV and the services who support themlast_img read more

Elon Musk Says True SelfDriving Teslas Could Be Ready in 2020

first_img 2019 Entrepreneur 360 List –shares Entrepreneur Staff Add to Queue The only list that measures privately-held company performance across multiple dimensions—not just revenue. Next Article Tesla But he’s been wrong before. Entrepreneur Staff Despite the name, Tesla’s Autopilot feature will not safely drive you home from work or anywhere else. Of course, that hasn’t stopped brazen Tesla owners from abusing the system (one was even allegedly drunk and asleep behind the wheel).But according to Tesla co-founder and CEO Elon Musk, true self-driving Tesla vehicles will be available next year.Related: The Daily Schedules of Jeff Bezos, Elon Musk, Oprah Winfrey and Other Famous Business Billionaires“I think we will be ‘feature complete’ on full self-driving this year, meaning the car will be able to find you in a parking lot, pick you up, take you all the way to your destination without an intervention this year,” Musk said during a podcast interview, as reported by Wired. “I am certain of that. That is not a question mark.”Of course, Musk has been off with his predictions in the past — just look at the whole production debacle he landed his company in after promising Tesla would manufacture 20,000 Model 3 cars a month by December of 2017. Yet still, Musk was at it again yesterday.Meant to say annualized production rate at end of 2019 probably around 500k, ie 10k cars/week. Deliveries for year still estimated to be about 400k.— Elon Musk (@elonmusk) February 20, 2019 Apply Now » 2 min read Image credit: Bloomberg | Getty Images February 20, 2019 Elon Musk Says True Self-Driving Teslas Could Be Ready in 2020last_img read more

How to Clean Up an Online Reputation

first_img Sarah Jacobsson Purewal How to Clean Up an Online Reputation Add to Queue Free Webinar | July 31: Secrets to Running a Successful Family Business If you own a small or medium business, a good reputation — online and offline — is clearly key to your success. The stakes are also high for individuals, who can win or lose jobs based upon how they appear in Web search results.The Internet can overwhelm users with information, so anything negative — especially if it appears high in search results — can have a drastically harmful effect on your success and how people see you.Among U.S. recruiters, 70 percent have rejected candidates based on their online reputation — and yet only 7 percent of Americans believe that their online reputation can affect their job search, according to a 2010 study by Microsoft and Cross-Tab Market Research. A potential customer who searches for your business online is a lot like a recruiter, trying to find the best company for the job.Ignoring how you or your company appears in search results and on ratings Websites has arguably never been more perilous.One significant figure in the recently altered relationship between businesses and search engines is Vitaly Borker, owner of retail eyewear Website DecorMyEyes.com, who told the New York Times in November that his unconventional search engine optimization (SEO) strategy worked like a charm: Borker harassed customers, directing them to vent on the Internet. His Website thus climbed higher in Google’s search results, bolstered by the many links from established review Websites.Google immediately reworked its code and buried DecorMyEyes along with other businesses it deemed “bad.” Now that Google no longer rewards bad customer service with top spots in searches, it’s a good time to examine how your business can get more positive attention in legitimate ways.Should You Pay for Online Reputation Management?Deciding to take control of your online reputation is a daunting task, and you may be tempted just to hire someone to do it for you. Online reputation management companies abound on the Internet — claiming everything from 100 percent success rate (or your money back) to a “special technology” that reorders search results.Such companies may be worth looking into, but there is no magical way to erase content from the Internet. Once something is uploaded to the Web, it’s impossible for you or a third party to remove it without help from the administrator of the Website where it appears.It’s even harder to remove content from search engines (like Google) that cache their results and enable surfers, with the click of the Cached link, to view content that has been “removed.” In addition, the Internet Archive’s Wayback Machine stores records of Websites dating back to the 1990s.Organizations such as ReputationDefender, RemoveYourName, and Integrity Defenders offer business packages to help you take on your online reputation. Essentially, however, these services focus on two tasks: requesting that negative information about you or your company be taken down, and helping you create new content to displace the negative content.ReputationDefender, which is perhaps the best-known reputation-oriented service, charges between $3000 and $10,000 to monitor your reputation. RemoveYourName and Integrity Defenders are a bit cheaper; their packages start at $3000 and $630, respectively. Often the quoted prices are just a starting point. ReputationDefender charges extra, for example, for helping you get rid of unsavory remarks that they uncover.Here are some key points to remember if you decide to hire an online reputation management company:Weigh any negative reviews of the company more heavily than you normally would. Remember, these companies are in the business of defending and rehabilitating reputations; if 10 “bad” reviews of their own service get through, imagine how many others they may have buried.No company has the magical power to automatically remove negative reviews from the Internet.Consider the benefits of a service that charges monthly versus a flat-fee service. Monthly services, such as BrandsEye, will constantly monitor your reputation. Flat-fee services, such as RemoveYourName, will spend as much time as it takes to get results. If you’re looking to remove specific negative reviews, a flat-fee service might be best for you; but if you just want someone to monitor your reputation, a monthly service makes more sense.It’s entirely possible that a reputation-monitoring service won’t be able to help you, or that the service’s efforts may backfire. In the case of Ronnie Segev, ReputationDefender and a blog called The Consumerist ended up in a spitting match after ReputationDefender requested that an article about Segev be removed.If you don’t have room in your budget for professional reputation management — or if you’ve decided that the service doesn’t justify the price — you can take on tracking and managing your online reputation by yourself.Step 1: Track Your Online PresencePerform a search for your company name in a general search engine, such as Google or Bing. Be sure to search not only for your company’s name, but also for related keywords, possible misspellings, and phrases (utilizing quotation marks). Note any negative reviews and where your company’s Website appears in relation to them (higher or lower). Cross-check your search on other search engines. For tips on effective ways to perform more-detailed searches, see “28 Time-Saving Tricks for Google, Facebook, and More.”Run site-specific searches on relevant Websites, including social media Websites such as Facebook and Twitter, review Websites like Yelp and Kudzu, and consumer advocacy sites such as GetSatisfaction and Ripoff Report. To perform a site-specific search of reviews of cupcake makers on Yelp, for example, type the following into Google: cupcake site:yelp.comSearch for individuals if you want to track the information available about you or your colleagues on people search engines such as Spokeo. Though most of these sites simply grab information that’s publicly available from other sources, you can try contacting them directly to request that they not present all the data to the public.Sign up for alerts from search engines. Google Alerts allows you to track search terms by type. The service will send any new mentions of your search term to your inbox daily, weekly, or in real time.Consider using BrandsEye or a similar service. This is one part of the process where paying for a service can definitely be useful. BrandsEye, which costs about $100 per month, not only tracks your online presence, but analyzes it, too. BrandsEye weighs each mention of your company as coming from an important or unimportant source and gauges how much effect each mention has on your overall reputation (similar to the way the Google search algorithm supposedly works).Step 2: Address the IssuesRead the reviews, both negative and positive. People usually spend more time reviewing services they feel strongly about, whether that feeling is love or hate. You can thus use negative online reviews constructively, especially if reviewers bring up legitimate complaints.Contact Websites if you encounter any false or unnecessarily vindictive reviews, and request that they be removed.Respond to customer complaints by apologizing and offering your side of the story. Then if someone later sees the negative comment about your company, they’ll also see that you’re committed to fixing and fostering good relationships with your customers. No matter how tempting it is, never trade insults with the customer — it’s harder for potential customers to identify with you than with a fellow consumer.Step 3: Connect and Create ContentConnect with your customers via social networking Websites. It’s not enough to have a Facebook page or a Twitter account that you post dry, business-related updates to — you have to engage your customers and help them get to know you, your business, and your brand. Content should be interesting — now is not the time to pitch your business or products — and try to encourage feedback from your followers.Create original content for the search engines, to displace any negative content that is currently popping up. This may take the form of anything from blog posts to informative articles to contests.Never “astroturf” by posting fake reviews, no matter how Web-savvy you are. If you’re found out, you’ll lose the respect of your customers, and you could also face legal trouble.Online reputation management might seem like a full-time job, but that’s not necessarily the case. If you take the steps to gauge the general tone of your brand’s online presence and discover that you’re doing a pretty good job, retaining a professional reputation defense company to obliterate one or two bad reviews makes little sense.If, on the other hand, your brand has a less-than-stellar reputation on the Internet, be aware that there is no one-step route to a rehabilitated rep; slow and steady relationship building is the most effective way to gain the reputation you desire. In most instances, a small business’s marketing teams should be able to handle online reputation management, since much of the task involves basic social networking and Website upkeep, along with reaching out to the clientele.Unfortunately, bad things have a way of snowballing — or “going viral” — on the Internet, so it’s possible that a bad hit to your reputation can become a big deal if you handle it poorly or fail to handle it at all. In these situations, having someone — whether it be a professional company or a full-time staff member — dedicated to protecting your reputation can be very helpful. If your online reputation is getting too hot to handle, for whatever reason, bringing in professional help should remove some of the stress. But no matter how professional a company or individual dedicated to online reputation management may be, ultimately they can’t do anything that you couldn’t do yourself with enough time and persistence.  9 min read January 14, 2011 Marketingcenter_img Controlling how you appear in search results and on social networking sites doesn’t have to be hard. Brought to you by PCWorld Learn how to successfully navigate family business dynamics and build businesses that excel. Next Article –shares Register Now »last_img read more

Salesforceorg Announces New Grants to Fuel Education and Workforce Development in India

first_img Fuel EducationFuture Ready programsIvyWorksmarketing cloudNewsSalesforceStephannie Bailey Previous ArticleBlock.one Introduces “Voice” to Bring Alignment and Transparency to Social MediaNext ArticleVoicesense Wins Excellence in Customer Service’s Technology of the Year Award $1.15 million in grants will fund programs for Indianapolis Public Schools Education Foundation and Ivy Tech FoundationSalesforce.org announced $1.15 million in grants for Indianapolis Public Schools Education Foundation, in support of Indianapolis Public Schools (IPS), and for Ivy Tech Foundation, in support of Ivy Tech Community College, as part of the company’s commitment to investing in Future Ready programs.Expanding Partnership with Indianapolis Public SchoolsBuilding on a strong partnership developed in the 2018-19 school year, Salesforce.org donated $650,000 to IPS. This grant will support three professional development pilot programs designed to increase principal effectiveness, improve new teachers’ transition to the classroom and strengthen the support that district staff provides to individual schools—ultimately driving better results for students.In 2018, Salesforce.org kicked off its partnership with IPS, donating $500,000 to provide a specialized IT education pathway for 137 students and three new computer labs with take-home devices. The partnership also supported the district’s “3E’s strategy” to ensure all IPS students graduate on time and were prepared to enroll in a two- or four-year college or university, gain employment at a livable wage, or enlist in the armed services.“We are grateful and humbled by the generosity of Salesforce.org’s investment in Indianapolis Public Schools,” said IPS Interim Superintendent Aleesia Johnson. “Over the next year, this partnership with Salesforce.org will enable IPS to enact strategic human capital and talent management projects that will positively affect thousands of IPS educators and central services team members. We look forward to the collaboration ahead and are thankful for the continued support from Salesforce.org.”“As IPS’s primary philanthropic partner, we are pleased to play a role in expanding Salesforce.org’s investment in the district,” said Stephannie Bailey, Indianapolis Public Schools Education Foundation Executive Director. “This significant financial commitment will allow the district to accelerate programming designed to attract, retain and empower educators and employee talent across IPS.”Marketing Technology News: StarfishETL Partners with PeopleSense, Inc.Investing in the Future Workforce of IndianapolisSalesforce.org donated $500,000 to Ivy Tech, which they will use over two years to establish an Information Technology Career Development model that incorporates tailored career development support for IT students from enrollment through graduation to better prepare them for success in IT careers. This tailored career development support includes career coaching, soft-skill training and development, stackable credentials, tutoring, employer networking opportunities and designated lab space.Last year, Salesforce.org funded 25 internships to support Ivy Tech’s IvyWorks, in partnership with Indy Women in Tech (IWiT). IWiT is designed to help women who want to shift their careers, including stay-at-home mothers and women who want to increase skills and certifications in their current careers, earn a credential in Information Technology.“As tech opportunities continue to grow in Indianapolis, Ivy Tech is committed to providing our students with the knowledge, skills and hands-on training needed for success,” said Dr. Kathleen Lee, chancellor of Ivy Tech Indianapolis. “This investment from Salesforce.org will not only benefit students and faculty in Ivy Tech’s IT programs, but also industry employers, strengthening Indiana’s economy.”Commitment to Training the Workforce of the FutureLast month, Salesforce pledged to train one million Americans with the skills needed to succeed in the jobs of today and tomorrow. Salesforce offers training and reskilling opportunities through the following programs:Trailhead: Salesforce’s fun, online learning platform to learn hard and soft skills on Salesforce.Futureforce: Salesforce’s university recruiting and in-house internship program cultivates the next generation of talent through direct work experience.Vetforce: Salesforce’s job training and career accelerator program for military service members, veterans and spouses connects virtual learners to free training, classes and career opportunities in the Salesforce ecosystem.Pathfinder Program: A four-month joint workforce training program with Deloitte, prepares participants for full-time jobs as certified Salesforce administrators and Salesforce developers.Marketing Technology News: Sauce Labs Named Gold Stevie Award Winner for Best Software Development Solution in 2019 American Business AwardsCommitment to IndianapolisSalesforce, the global leader in CRM, has more than 37,000 employees worldwide and nearly 2,000 in Indianapolis. Salesforce is committed to giving back to the communities where employees live and work. In Indianapolis, Salesforce has partnered with leading organizations in the area to further develop technology talent including TechPoint, the IndyChamber and the Indiana Technology & Innovation Association. Additionally, Salesforce has committed to training 500 workers on Salesforce technology by 2020 through its Pathfinder program.Salesforce Indianapolis employees have volunteered more than 250,000 hours at organizations including Indianapolis Public Schools, Habitat for Humanity and Junior Achievement. In addition, Salesforce.org has donated nearly $2 million in grants towards Indianapolis Public Schools, Ivy Tech and Techpoint Foundation for Youth.“We’re proud to support our local schools and partner with leaders who are creating change in our community,” said Bob Stutz, CEO of Marketing Cloud and Chief Analytics Officer, Salesforce. “With innovative programs to support professional and IT development, we’re empowering workforce of tomorrow with the skills needed to succeed.”Marketing Technology News: New iPad App for Food and Beverage Professionals Takes Menus from Paper to Fully Digital in Less than an Hour Salesforce.org Announces New Grants to Fuel Education and Workforce Development in India PRNewswireJune 7, 2019, 1:18 pmJune 10, 2019 last_img read more

Rivian patents removable auxiliary battery for its R1T electric pickup truck

first_imgSource: Charge Forward Rivian has filed for a patent to expand the energy capacity of its upcoming R1T electric pickup truck through a novel auxiliary battery which can be added to the truck’s bed after manufacture.The patent was filed last year, published last month and today is marked as “pending” by the US patent office. more…The post Rivian patents “removable auxiliary battery” for its R1T electric pickup truck appeared first on Electrek.last_img